Medicover Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Los beneficios de Medicover han disminuido a una tasa media anual de -8.5%, mientras que en la industria Healthcare los beneficios crecieron en un 20.5% anualmente. Los ingresos han ido creciendo a una tasa media de 17.6% al año. La rentabilidad financiera de Medicover es de 3%, y sus márgenes netos son de 1%.

Información clave

-8.5%

Tasa de crecimiento de los beneficios

-9.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	8.1%
Tasa de crecimiento de los ingresos	17.6%
Rentabilidad financiera	3.0%
Margen neto	1.0%
Próxima actualización de resultados	12 Feb 2025

Actualizaciones de resultados anteriores recientes

The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Nov 07

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04

Recent updates

The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Nov 07

Here's What To Make Of Medicover's (STO:MCOV B) Decelerating Rates Of Return

Oct 24

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Apr 22

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Mar 05

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Feb 11

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Jun 12

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

May 27

Is Medicover (STO:MCOV B) Using Too Much Debt?

May 12

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Feb 16

Is Medicover (STO:MCOV B) Using Too Much Debt?

Jan 30

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Dec 30

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Dec 17

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Oct 30

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Oct 16

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Sep 09

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Jul 25

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Jul 12

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Jun 13

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

May 29

Desglose de ingresos y gastos

Cómo gana y gasta dinero Medicover. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OM:MCOV B Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	1,998	20	330
30 Jun 24	1,911	23	316
31 Mar 24	1,826	22	304
31 Dec 23	1,746	18	297
30 Sep 23	1,682	8	297
30 Jun 23	1,610	5	294
31 Mar 23	1,548	1	280
31 Dec 22	1,510	12	271
30 Sep 22	1,489	37	270
30 Jun 22	1,455	59	253
31 Mar 22	1,442	88	248
31 Dec 21	1,377	102	232
30 Sep 21	1,299	93	212
30 Jun 21	1,226	90	205
31 Mar 21	1,076	52	198
31 Dec 20	998	26	196
30 Sep 20	930	14	193
30 Jun 20	879	4	183
31 Mar 20	884	16	171
31 Dec 19	844	23	158
30 Sep 19	796	19	151
30 Jun 19	751	19	144
31 Mar 19	709	20	137
31 Dec 18	672	22	129
30 Sep 18	643	28	124
30 Jun 18	620	26	120
31 Mar 18	600	23	117
31 Dec 17	580	19	113
30 Sep 17	560	10	110
30 Jun 17	540	9	106
31 Mar 17	522	6	104
31 Dec 16	497	4	99
31 Dec 15	416	8	79
31 Dec 14	365	4	71

Ingresos de calidad: MCOV B tiene una única gran pérdida de €9.5M que afecta a sus resultados financieros de los últimos 12 meses de 30th September, 2024.

Margen de beneficios creciente: Los actuales márgenes de beneficio (1%) de MCOV B son superiores a los del año pasado (0.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de MCOV B han disminuido en un 8.5% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de MCOV B en el último año (146.3%) supera su media de 5 años (-8.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de MCOV B en el último año (146.3%) superó al de la industria Healthcare 29.5%.

Medicover Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings released: €0.029 loss per share (vs €0.007 loss in 3Q 2023)

Medicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025

Second quarter 2024 earnings released: EPS: €0.042 (vs €0.037 in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Recent updates

Insider recently bought kr498k worth of stock

The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings released: €0.029 loss per share (vs €0.007 loss in 3Q 2023)

Medicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025

Here's What To Make Of Medicover's (STO:MCOV B) Decelerating Rates Of Return

Medicover AB (publ) Announces Nomination Committee for the AGM 2025

Medicover AB (publ), Annual General Meeting, Apr 25, 2025

Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024

Second quarter 2024 earnings released: EPS: €0.042 (vs €0.037 in 2Q 2023)

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

General Legal Counsel recently sold kr1.2m worth of stock

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

New minor risk - Earnings quality

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Dividend of €0.12 announced

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Full year 2023 earnings: EPS exceeds analyst expectations

Now 24% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Consensus EPS estimates increase by 27%

Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Independent Chairman recently bought kr3.9m worth of stock

New minor risk - Earnings quality

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Chief Information Officer recently bought kr321k worth of stock

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

Is Medicover (STO:MCOV B) Using Too Much Debt?

Consensus EPS estimates fall by 10%

Now 21% undervalued after recent price drop

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 72%

Now 23% undervalued

Full year 2022 earnings: Revenues in line with analyst expectations

Medicover AB (publ) Proposes Dividend for 2022

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Consensus EPS estimates fall by 26%

Is Medicover (STO:MCOV B) Using Too Much Debt?

Investor sentiment improved over the past week

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.